nmt

NMT-IN-1 is a potent inhibitor of N-nutyltransferase (NMT), with IC50 of 31μM for TbNMT and 66μM for hNMT. NMT-IN-1 is a potential compound for the treatment of African trypanosomiasis.

4-PivO-NMT chloride is an indole derivative-based regulator of the AMPK signaling pathway. It modulates neurogenesis or neurite outgrowth by influencing AMPK activity and holds potential for research in neurological disorders, pain, and inflammation.

NMT-IN-7 is an inhibitor of N-myristoyltransferase (NMT) with an IC50 of 2.1 nM for HsNMT1M and demonstrates toxicity with an IC50 of 0.6 nM against SU-DHL-10 cells. It can be utilized as an ADC cytotoxin.

DNMT1 HDAC-IN-1 (compound (R)-23a), a potent dual inhibitor targeting both DNMT1 and HDAC, exhibits impressive inhibitory effects specifically on HDAC1 (HDAC1:IC50=0.05 μM), a major HDAC isoform that interacts with DNMT1 across multiple protein complexes involved in the transcriptional silencing of TSGs. This compound has been shown to remodel the tumor immune microenvironment and induce tumor regression, effectively reversing cancer-specific epigenetic abnormalities.

NNMT-IN-7 (Compound 4e) is an NNMT inhibitor with an IC50 of 505.7 µM. It is useful for research in metabolic and chronic diseases.

CpNMT-IN-1 (Compound 11e) is an inhibitor of N-myristoyltransferase (CpNMT) with an IC50 value of 2.5 μM. It also inhibits the growth of microsporidia, demonstrating an EC50 value of 6.9 μM.

DNMT-IN-4 (Compound 4d) is a DNMT inhibitor with an IC50 value of 5.78 µM. It induces apoptosis and exhibits anticancer activity.

DNMT1-IN-5 (Compound 55) is an inhibitor of DNMT, specifically targeting DNMT1 and DNMT3A, with IC50 values of 2.42 μM and 14.4 μM, respectively. It demonstrates antiproliferative effects across various cancer cell lines (TMD-8, DOHH2, MOLM-13, THP-1, RPIM-8226, and HCT116) with IC50 values ranging from 0.19 to 2.37 μM. The compound induces G2 M phase cell cycle arrest and apoptosis in TMD-8 and DOHH2 cells. Additionally, DNMT1-IN-5 exhibits antitumor efficacy in a TMD-8 xenograft mouse model.

NMTCA (NMTPRO) is a sulfur-containing N-nitrosamino acid used as an endogenous nitrosation indicator in gas chromatography-thermal energy analysis (GC-TEA).

DNMT3A-IN-1 is a selective and potent DNMT3A inhibitor. DNMT3A-IN-1 exhibits inhibitory activity against DNMT3A with a KI ranging from 9.16-18.85 μM (AdoMet) and 11.37-23.34 μM (poly dI-dC).

NNMT-IN-3 (compound 14) is a potent and selective inhibitor of nicotinamide N-methyltransferase (NNMT), with IC50 values of 1.1 nM in cell-free assays and 0.4 μM in cell-based assays. NNMT-IN-3 can be utilized in studies of obesity, cancer, type II diabetes, and skeletal sarcopenia, among other diseases.

PNMT-IN-1 (inhibitor 4) is a selective second generation inhibitor [1] of phenylethanolamine N-methyltransferase (PNMT), exhibiting a Ki value of 1.2 nM and an IC50 value of 81 nM. Additionally, it disrupts the activity of DNMT1 and DNMT3b, with IC50 values of 61 μM and 17 μM, respectively, and antagonizes the action of epinephrine.

NNMT-IN-4 (compound 38) is a selective, uncompetitive inhibitor of nicotinamide N-methyltransferase (NNMT) with in vitro biochemical and cell-based assay IC50 values of 42 nM and 38 nM, respectively. It demonstrates favorable pharmacokinetics pharmacodynamics (PK PD) and safety profiles, excellent oral bioavailability, and promising pharmaceutical properties. NNMT-IN-4 serves as an in vivo chemical probe for NNMT [1].

DNMT HDAC-IN-1 (Compound 15a) is a dual DNMT and HDAC inhibitor with IC50 values of 56.84 nM for HDAC1 and 17.39 nM for HDAC6. DNMT HDAC-IN-1 can induce apoptosis and is useful in tumor research.

DNMT-IN-3 is a DNA Methyltransferase (DNMT) inhibitor with an IC50 of 60 nM against Plasmodium falciparum (Plasmodium), demonstrating antimalarial activity and suitability for malaria-related research [1].

NNMTi (5-Amino-1-methylquinolinium) is a substrate site-targeting, selective nicotinamide N-methyltransferase (NNMT) inhibitor (IC50 = 1.2 μM; 50 μM SAM, 100 μM NCA) that reduces 3T3-L1 lipogenesis (EC50 = 30μM) and adipocytes 1-methylnicotinamide level (EC50 = 2.3 μM) without affecting related methyltransferases & enzymes in the NAD+ salvage pathway

DDD100097 is a potent N-myristoyltransferase inhibitor with potential inhibitory effects on Trypanosoma brucei, which can be used to study neurological disorders.

DDD85646 is an inhibitor of T. brucei N-myristoyltransferase with a Ki of 1.44 nM, an IC50 of 2 nM and an EC50 of 2 nM. The IC50 of hNMT is 4 nM.

tris(dibenzylideneacetone)dipalladium (Tris DBA) is a N-myristoyltransferase-1 (NMT-1) inhibitor

DCAT Maleate is an inhibitor of N-methyl transferases (NMT). DCAT Maleate methylate non-methylated pre-neurotoxins to prevent the formation of Parkinson's syndrome neurotoxins.

Lifibrate is an inhibitor of cholinephosphotransferase (CPT), phosphatidyl-N,N-dimethylethanolamine N-methyltransferase (PDE-NMT), and phosphatidyl-N-methylethanolamine N-methyltransferase (PME-NMT).

SC-58272 is an inhibitor of N-myristoyltransferase (Nmt), a target for anti-fungal and anti-viral therapy.

PCLX-001 is a small-molecule compound that acts as an orally active inhibitor of N-myristoyltransferase (NMT), specifically targeting NMT1 and NMT2 with IC50 values of 5 nM and 8 nM, respectively. This compound demonstrates anti-tumor effects and effectively inhibits the early signaling of B-cell receptor (BCR). Consequently, PCLX-001 is a valuable tool for researching B-cell malignancies [1] [2].